EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSCHAG00000005178
Gene Symbol: GABRG2
1 Cross references
213 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSCHAG00000008396
Gene Symbol: GABRG3
3 Cross references
222 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSCHAG00000025500
Gene Symbol: GABRG3
3 Cross references
163 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSCHAG00000013812
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSCHAG00000021359
Gene Symbol: LOC105903872
3 Cross references
207 Possible Orthologues:

Glucokinase

Ensembl ID : ENSCHAG00000012544
Gene Symbol: GCK
3 Cross references
216 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSCHAG00000009079
Gene Symbol: GBA1
1 Cross references
255 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSCHAG00000009528
Gene Symbol: GRIA2
3 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSCHAG00000024462
Gene Symbol: GRIN2A
1 Cross references
223 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSCHAG00000009255
Gene Symbol: GRIN2B
3 Cross references
261 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSCHAG00000015022
Gene Symbol: GRIN2C
1 Cross references
247 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2d

Ensembl ID : ENSCHAG00000004349
Gene Symbol: GRIN2D
1 Cross references
213 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).